Recent Updates
Recently added Catalysts
TNGX Positive Sentiment

Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

Tuesday, August 26, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Tango Therapeutics, a clinical-stage biotechnology company, announced that its President and CEO, Dr. Barbara Weber, will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on September 3. The event will feature a live webcast, ensuring broad access for interested parties. Following the event, a replay will be available for 90 days on the company's website. This participation highlights Tango's role in advancing precision medicine in cancer treatment.
Price reaction · baseline $6.72 (2025-08-25 close) · hit after-hours · clean, no other TNGX news in the window
day 0 close
-0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Tango Therapeutics is participating in a prestigious healthcare conference.
  • The event allows for direct engagement with the company's leadership.
  • The live webcast increases accessibility for investors and stakeholders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
1%
average across 2 past catalysts
Cash runway
~78 mo
Minimal dilution risk
Lead asset
Perindopril-indapamide
Phase 3 · Diabetes Mellitus, Type 2

Full Press Release Details

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Wednesday, September 3 at 2:45-3:15 PM ET.
The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
Investors and Media:

Frequently Asked Questions

When is Barbara Weber scheduled to speak at the conference?

Barbara Weber will speak on September 3, 2025, from 2:45 to 3:15 PM ET.

Where can I watch the live webcast of the event?

The live webcast can be found on the 'Investors' page under 'Events & Presentations'.

How long will the webcast replay be available?

The webcast replay will be available for 90 days after the presentation.

What is the focus of Tango Therapeutics?

Tango Therapeutics focuses on discovering novel drug targets for cancer precision medicine.

What principle does Tango employ in its therapy development?

Tango uses the genetic principle of synthetic lethality to develop cancer therapies.

ShareAdd on Google
Tags: TNGX Viatris Investor Conferences Healthcare Tango Therapeutics Cantor Global Healthcare Conference biotechnology cancer treatment
Last updated: Aug 26, 2025

Biotech snapshot

Cash runway
$1014M liquidity · $13M/mo burn
~78 mo
Minimal dilution risk
Lead asset
Perindopril-indapamidePhase 3
Diabetes Mellitus, Type 2 →

Catalyst track record

+24%
best trade around TNGX's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for TNGX.

See every catalyst's timing & PoA →